Development of the Parkinson’s disease gene therapy that UniQure was previously involved in...
- ViiV adds another innovative treatment to its growing HIV arsenal
- Action Medical Research: celebrating decades of discovery
- Drug development: the researchers driving an open-science approach
- Gene genie: can CRISPR-Cas9 deliver on its promise to transform genome therapy?
- Drugs from corn? Harvesting Mirexus’ phytoglycogen nano-particle
Parkinson’s gene therapy development to restart in summer 2019
Development of the Parkinson’s disease gene therapy that UniQure was previously involved in will be restarted in a Phase II trial this summer with the help of a private-public entity.
Minerva to explore therapy in treatment-naïve schizophrenia and more
Minerva Neurosciences’ MIN-101 (roluperidone) is being considered for a future trial in treatment-naïve schizophrenia patients and additional indications with apathy symptoms.
ViiV adds another innovative treatment to its growing HIV arsenal
The FDA has approved Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus (HIV) in adults who have not previously received antiretroviral therapy (ART).
NDAs submitted to the FDA for the first oral GLP-1 receptor agonist
Novo Nordisk has submitted NDAs for what could be the first ever oral GLP-1 based treatment for type II diabetes. What could this mean for the GLP-1 market?
Boehringer partners PureTech to develop immuno-oncology candidates
Boehringer Ingelheim has formed an alliance with US-based PureTech Health to develop new drug candidates for a variety of targets using lymphatic targeting technology.
Designed for the User
Ask founder and president of Erdmann Design Raimund Erdmann what innovation means and you may be surprised by his response. He suggests that creating new devices that make a big difference to patients isn't about harnessing the very latest technology, but it is about obsessing over the experience of users and having a true 'start-up' mentality.
Pulmatrix and Cipla collaborate to develop asthma drug
Pulmatrix and Cipla Technologies have signed a definitive agreement to jointly develop and commercialise Pulmazole to treat allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.
Gilead and insitro team up to develop treatment for NASH
Gilead Sciences has partnered with insitro, a data-driven drug discovery startup, to leverage an artificial intelligence based platform for the discovery and development of new drugs to treat nonalcoholic steatohepatitis.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.